

## **MYOBLOC (rimabotulinumtoxinB)**

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

**(Archived 1/22/19)**

**Myobloc** is a commercial form of botulinum toxin (a neurotoxin which inhibits the release of acetyl choline from the presynaptic membrane of the neuromuscular junction, leading to paresis or paralysis).

**Authorization:** Myobloc is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and associated neck pain

**Dosing:** 2,500 to 5,000 Units (0.5cc-1cc) divided among affected muscles

**PRECAUTIONS:** should be administered by a practitioner specially trained in its use; distant spread of toxin beyond site of injection [U.S. Boxed Warning]; loss of efficacy due to antibody formation after prolonged use; unwanted reactions at injection sites (bleeding; excessive paresis); dry cornea/corneal abrasion from reduced blink reflexes

**DRUG INTERACTIONS:** neuromuscular blocking agents; anticholinergic agents; aminoglycosides

**Note:** Onabotulinum (Botox), abobotulinumtoxin (Dysport) and rimabotulinumtoxinB (Myobloc) have unique dosing, as spelled out in each agent's prescribing information. It is important that physicians be familiar with the respective dosing guidelines for each agent and be prepared to make appropriate treatment decisions in any clinical setting.

**Note:** The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration.

## REFERENCES

1. Brashear A, Lew MF, Dykstra DD, et al, "Safety and Efficacy of NeuroBloc (Botulinum Toxin Type B) in Type A-Responsive Cervical Dystonia," *Neurology*, 1999, 53(7):1439-46.
  
2. Brin MF, Lew MF, Adler CH, et al, "Safety and Efficacy of NeuroBloc (Botulinum Toxin Type B) in Type A-Resistant Cervical Dystonia.," *Neurology*, 1999, 53(7):1431-8.
  
3. "Clinical Use of Botulinum Toxin," *Arch Neurol*, 1991, 48(12):1294-8.

### Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

| Revision Date | Content Revised (Yes/No) | Contributors                               | Review/Revision Notes |
|---------------|--------------------------|--------------------------------------------|-----------------------|
| 1/24/17       | No                       | Catherine Sanders, MD; Robert Sterling, MD | Annual review         |
| 1/23/18       | No                       | Catherine Sanders, MD; Robert Sterling, MD | Annual review         |
| 1/22/19       | No                       | Catherine Sanders, MD; Robert Sterling, MD | Archived – check MCG  |